These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 20855829)

  • 1. Randomized phase II trials: misleading and unreliable.
    Stewart DJ
    J Clin Oncol; 2010 Nov; 28(31):e649-50; author reply e651-3. PubMed ID: 20855829
    [No Abstract]   [Full Text] [Related]  

  • 2. Examining heterogeneity in phase II trial designs may improve success in phase III.
    Tuma RS
    J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
    [No Abstract]   [Full Text] [Related]  

  • 3. Criticism of tumor response criteria raises trial design questions.
    Twombly R
    J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
    [No Abstract]   [Full Text] [Related]  

  • 4. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Developing drugs that do not cause tumor regression.
    Stadler W
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):654-5. PubMed ID: 16258462
    [No Abstract]   [Full Text] [Related]  

  • 7. Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?
    Rubinstein LV; Dancey JE; Korn EL; Smith MA; Wright JJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1422-3. PubMed ID: 17895470
    [No Abstract]   [Full Text] [Related]  

  • 8. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A strategic framework for novel drug development in multiple myeloma.
    Anderson KC; Hannah AL; Pazdur R; Farrell AT
    Br J Haematol; 2007 Jul; 138(2):153-9. PubMed ID: 17593022
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
    Sharma MR; Maitland ML; Ratain MJ
    Cancer J; 2009; 15(5):426-30. PubMed ID: 19826363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research outcomes and recommendations for the assessment of progression in cancer clinical trials from a PhRMA working group.
    Stone AM; Bushnell W; Denne J; Sargent DJ; Amit O; Chen C; Bailey-Iacona R; Helterbrand J; Williams G;
    Eur J Cancer; 2011 Aug; 47(12):1763-71. PubMed ID: 21435858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcome.
    Monzon JG; Hay AE; McDonald GT; Pater JL; Meyer RM; Chen E; Chen BE; Dancey JE
    Eur J Cancer; 2015 Nov; 51(17):2501-7. PubMed ID: 26338195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Other paradigms: randomized discontinuation trial design.
    Stadler W
    Cancer J; 2009; 15(5):431-4. PubMed ID: 19826364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Sufficient life expectancy": an amazing inclusion criterion in cancer phase II-III trials.
    Penel N; Clisant S; Lefebvre JL; Adenis A
    J Clin Oncol; 2009 Sep; 27(26):e105. PubMed ID: 19667257
    [No Abstract]   [Full Text] [Related]  

  • 17. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose density in breast cancer: a simple message?
    Lin NU; Gelman R; Winer EP
    J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical trials referral resource. Current phase II and phase III clinical trials in the treatment of colorectal cancer.
    Mooney MM; Schoenfeldt M
    Oncology (Williston Park); 2004 Oct; 18(11):1396, 1401, 1404 passim. PubMed ID: 15609469
    [No Abstract]   [Full Text] [Related]  

  • 20. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.